Next Article in Journal
HER2 in Breast Cancer Stemness: A Negative Feedback Loop towards Trastuzumab Resistance
Next Article in Special Issue
HGF/Met Signaling in Cancer Invasion: The Impact on Cytoskeleton Remodeling
Previous Article in Journal
Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells
Previous Article in Special Issue
Hepatocyte Growth Factor, a Key Tumor-Promoting Factor in the Tumor Microenvironment
Article Menu
Issue 4 (April) cover image

Export Article

Open AccessReview
Cancers 2017, 9(4), 39; doi:10.3390/cancers9040039

Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment

1
Department of Pharmacology & Chemical Biology, University of Pittsburgh, Pittsburgh, PA 15213, USA
2
University of Pittsburgh Cancer Center, Pittsburgh, PA 15213, USA
*
Author to whom correspondence should be addressed.
Academic Editor: Jill Siegfried
Received: 6 March 2017 / Revised: 14 April 2017 / Accepted: 20 April 2017 / Published: 24 April 2017
(This article belongs to the Special Issue Hepatocyte Growth Factor Pathway in Cancer)
View Full-Text   |   Download PDF [498 KB, uploaded 24 April 2017]   |  

Abstract

Aberrant signaling of the hepatocyte growth factor (HGF)/c-Met pathway has been identified as a promoter of tumorigenesis in several tumor types including head and neck squamous cell carcinoma (HNSCC). Despite a relatively low c-Met mutation frequency, overexpression of HGF and its receptor c-Met has been observed in more than 80% of HNSCC tumors, with preclinical and clinical studies linking overexpression with cellular proliferation, invasion, migration, and poor prognosis. c-Met is activated by HGF through a paracrine mechanism to promote cellular morphogenesis enabling cells to acquire mesenchymal phenotypes in part through the epithelial-mesenchymal transition, contributing to metastasis. The HGF/c-Met pathway may also act as a resistance mechanism against epidermal growth factor receptor (EGFR) inhibition in advanced HNSCC. Furthermore, with the identification of a biologically distinct subset of HNSCC tumors acquired from human papillomavirus (HPV) infection that generally portends a good prognosis, high expression of HGF or c-Met in HPV-negative tumors has been associated with worse prognosis. Dysregulated HGF/c-Met signaling results in an aggressive HNSCC phenotype which has led to clinical investigations for targeted inhibition of this pathway. In this review, HGF/c-Met signaling, pathway alterations, associations with clinical outcomes, and preclinical and clinical therapeutic strategies for targeting HGF/c-Met signaling in HNSCC are discussed. View Full-Text
Keywords: head and neck squamous cell carcinoma; HGF; c-Met; EMT; HPV; targeted therapies head and neck squamous cell carcinoma; HGF; c-Met; EMT; HPV; targeted therapies
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Rothenberger, N.J.; Stabile, L.P. Hepatocyte Growth Factor/c-Met Signaling in Head and Neck Cancer and Implications for Treatment. Cancers 2017, 9, 39.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top